What question did this study set out to answer?

The aim is to assess the persistent gaps in the supply of praziquantel in Italy and the efforts to address them.

April 15, 2026Open Access

Access to praziquantel in Italy: persistent gaps and ongoing responses amid a Europe-wide shortage

Key Points

The aim is to assess the persistent gaps in the supply of praziquantel in Italy and the efforts to address them.
Analysis of historical gaps in PZQ supply
Review of actions taken to restore access
Examination of interim solutions implemented
PZQ is not registered for human use in Italy, creating accessibility issues.
Europe-wide shortages have hindered importation efforts.
Interim solutions have been developed to improve access to PZQ in Italy.

Abstract

Abstract In Italy, praziquantel (PZQ) is not registered for human use and can be imported from European countries where it is authorized, according to a specific ministerial decree. Recent Europe-wide shortages, however, have made this route impractical, resulting in the unavailability of this essential medicine. This editorial summarizes historical gaps in supply, the actions undertaken, and the interim solutions implemented to restore PZQ access in Italy. The Italian experience highlights broader challenges related to essential medicines and underscores the need for coordinated national and European strategies to ensure stable and equitable availability. Graphical Abstract

AI से पूछें

Bookmark

View Full Paper